Join our daily newsletter At The Bell to receive exclusive market insights
- Imugene (IMU) receives a Notice of Allowance from the US Patent and Trademark Office for its PD1-Vaxx technology
- The patent protects the composition of matter and method of treatment for PD1-Vaxx in cancer until 2038
- PD1-Vaxx is a B-cell-activating immunotherapy for non-small cell lung cancer (NSCLC)
- Imugene says it has final preparations in place for a clinical trial combining PD1-Vaxx with Tecentriq, an immune checkpoint inhibitor, in the US and Australia
- IMU shares are up 5.56 per cent to 14 cents at 10:51 am AEDT
Immuno-oncology specialist Imugene (IMU) has been granted a patent in the United States for its lung cancer treatment product, PD1-Vaxx.
The company on Friday morning said it had received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for the patent, protecting the composition of matter and method of treatment in cancer for PD1-Vaxx until 2038.
PD1-Vaxx is a B-cell activating immunotherapy for non-small cell lung cancer (NSCLC). Imugene said it had final preparations in place for a PD1-Vaxx clinical trial in the US and Australia
The trial will determine the safety, efficacy, and optimal dose of PD1-Vaxx in combination with atezolizumab, an immune checkpoint inhibitor sold under the brand name Tecentriq, as either first-line therapy for NSCLC patients or for pre-treated patients.
“With the US being the largest healthcare market in the world, this is a particularly important patent to protect our PD1-Vaxx technology as we continue its development,” Imugene CEO Leslie Chong said.
“It’s vital to our business that we continue locking in intellectual property protection across the portfolio of assets.”
IMU shares were up 5.56 per cent to 14 cents at 10:51 am AEDT.
